ERBB2 and breast cancer: A meta-analysis for cohort randomized trials on women with HER2-positive early breast cancer disclosed that trastuzumab-based adjuvant chemotherapy derived benefit in disease-free survival, overall survival and recurrence to adjuvant chemotherapy, but did worse in recurrence on the central nervous system compared to the controls [8].